1-5 of 5
Marina Pajic
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Selected Alkylating Agents Can Overcome Drug Tolerance of G0-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice

Marina Pajic, Sohvi Blatter, Charlotte Guyader, Maaike Gonggrijp, Ariena Kersbergen, Aslι Küçükosmanoğlu, Wendy Sol, Rinske Drost, Jos Jonkers, Piet Borst, Sven Rottenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (22): 7020–7033.
https://doi.org/10.1158/1078-0432.CCR-17-1279
Published: 14 November 2017
View article titled, Selected Alkylating Agents Can Overcome Drug Tolerance of G<sub>0</sub>-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice
Open the PDF for Selected Alkylating Agents Can Overcome Drug Tolerance of G<sub>0</sub>-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice in another window
Includes: Supplementary data
Journal Articles

Abstract PL6-1: Resistance to targeted therapies in a realistic mouse breast cancer model

Piet Borst, Sven Rottenberg, Jos Jonkers, Serge Zander, Marina Pajic, Janneke Jaspers
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (7_Supplement): PL6-1.
https://doi.org/10.1158/1078-0432.TCME10-PL6-1
Published: 02 February 2016
View article titled, Abstract PL6-1: Resistance to targeted therapies in a realistic mouse breast cancer model
Journal Articles

Abstract A14: Lack of tumor eradication of chemotherapy-sensitive BRCA1;p53-deficient mouse mammary tumors

Sven Rottenberg, Marina Pajic, Ariena Kersbergen, Nikola Banishki, Guotai Xu, Jos Jonkers, Piet Borst
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (7_Supplement): A14.
https://doi.org/10.1158/1078-0432.TCME10-A14
Published: 02 February 2016
View article titled, Abstract A14: Lack of tumor eradication of chemotherapy-sensitive BRCA1;p53-deficient mouse mammary tumors
Journal Articles

Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial

Lorraine A. Chantrill, Adnan M. Nagrial, Clare Watson, Amber L. Johns, Mona Martyn-Smith, Skye Simpson, Scott Mead, Marc D. Jones, Jaswinder S. Samra, Anthony J. Gill, Nicole Watson, Venessa T. Chin, Jeremy L. Humphris, Angela Chou, Belinda Brown, Adrienne Morey, Marina Pajic, Sean M. Grimmond, David K. Chang, David Thomas, Lucille Sebastian, Katrin Sjoquist, Sonia Yip, Nick Pavlakis, Ray Asghari, Sandra Harvey, Peter Grimison, John Simes, Andrew V. Biankin
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (9): 2029–2037.
https://doi.org/10.1158/1078-0432.CCR-15-0426
Published: 30 April 2015
View article titled, Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial
Open the PDF for Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial in another window
Journal Articles

Gemcitabine and CHK1 Inhibition Potentiate EGFR-Directed Radioimmunotherapy against Pancreatic Ductal Adenocarcinoma

Fares Al-Ejeh, Marina Pajic, Wei Shi, Murugan Kalimutho, Mariska Miranda, Adnan M. Nagrial, Angela Chou, Andrew V. Biankin, Sean M. Grimmond, for the Australian Pancreatic Cancer Genome Initiative, Michael P. Brown, Kum Kum Khanna
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (12): 3187–3197.
https://doi.org/10.1158/1078-0432.CCR-14-0048
Published: 12 June 2014
View article titled, Gemcitabine and CHK1 Inhibition Potentiate EGFR-Directed Radioimmunotherapy against Pancreatic Ductal Adenocarcinoma
Open the PDF for Gemcitabine and CHK1 Inhibition Potentiate EGFR-Directed Radioimmunotherapy against Pancreatic Ductal Adenocarcinoma in another window
Includes: Supplementary data